The news: Biogen's treatment for early stage Alzheimer's disease received FDA approval this week for starting at-home use. Previously, Leqembi required biweekly treatments at specialty infusion centers for the first 18 months of treatment. The approval marks the first time eligible patients can begin therapy at home through self-administration.

Why it matters: The approval eliminates repeated infusion-center visits during the initial phase of therapy. By reducing the treatment burden, at-home initiation could help more eligible patients start and stay on treatment, particularly those facing transportation, caregiver, or other barriers, as well as those living in areas with limited infusion-center access.

Pharma companies see the at-home market as a chance to differentiate their drugs, and the new at-home start gives Biogen the edge over Eli Liily’s IV-infused Kisunla. Lilly is not developing an at-home version of Kisunla, but it is testing a next-generation Alzheimer's treatment designed for at-home administration.

Implications for health systems and providers: At-home treatment initiation will shift Alzheimer's care beyond the traditional infusion center model. That means health systems will need to rethink infusion center capacity, expand remote monitoring and patient support, and make patient and caregiver education a bigger part of Alzheimer's care. For providers, the focus will move from scheduling and managing infusions to identifying appropriate patients for home treatment, teaching patients and caregivers how to use the autoinjector, and monitoring side effects through a combination of remote and in-person care.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.